J Pharm Sci April 2021 PMID 33556387

Overview of Humira® Biosimilars: Current European Landscape and Future Implications.

Jill Coghlan, Hongliang He, Anna S Schwendeman

Mentions

9
Peak: 1 in Feb 2021
across 3 sources since Feb 2021

Extended reach

2,444
potential audience

Total likes

46

Video views

1,908

Mentions per month

Feb 2021 – Nov 2025

Where it's discussed

  • News6 articles
  • YouTube2 videos
  • X / Twitter1 posts

AI synopsis

What people are saying

Discussions show strong interest and recognition of the article’s importance, with comments on the decline in Humira's sales and market shifts to biosimilars, using tone and language that reflect curiosity and concern, indicating that the publication is seen as impactful in shaping future pharmaceutical landscapes.

AgreementModerate agreement

Most discussions acknowledge the importance of biosimilars and agree with the article's insights on market shifts and the sales decline of Humira®. There are mentions of biosimilars contributing to market changes, indicating support.

InterestHigh interest

Posts demonstrate high interest, with many discussing detailed market implications, patient switching behaviors, and future U.S. market entries, showing curiosity and investment in understanding the topic.

EngagementModerate engagement

Several comments reference specific data points, such as the 35% patient switch rate or sales figures, and analyze implications, reflecting a moderate level of deep engagement.

ImpactModerate impact

Participants believe the publication highlights significant market trends that could influence pharmaceutical practices and policy, suggesting a moderate to high perceived impact.

Abstract in brief

  • Humira® (adalimumab) has been a leading biologic drug with nearly $20 billion in sales in 2018, but faced a decline in 2019 after biosimilars entered the European market.
  • By late 2019, about 35% of European patients had switched to these biosimilars, contributing to a decrease in Humira®'s annual sales to around $19 billion.
  • The review discusses the impact of biosimilars on the adalimumab market, comparing their formulations, delivery, activity, and properties, while preparing the public for similar changes as these biosimilars are expected to enter the U.S. market in 2023.

Top posts

Most liked on X and Bluesky
JPharmSciences
@JPharmSciences · X

Overview of Humira® biosimilars: current European landscape and future implications https://t.co/hAhSCzYHgv

Feb 5, 2021 · 477 followers View post →

All mentions

JPharmSciences
@JPharmSciences · X

Overview of Humira® biosimilars: current European landscape and future implications https://t.co/hAhSCzYHgv

Feb 5, 2021 · 477 followers View post →
1 s2.0 S2589871X22000857 Main | PDF | Dementia | Methodology
News

... 10.1016/j. [84] B. Florescu, C. Filip, D. Rosca, F. Damsa, Peculiarities of ... 2021.02.003. 71, https://doi.org/10.1007/s12520-021-01320-5. [417] L ...

Dec 18, 2025 View →
23 PGProceedings | PDF | Cloud Computing | Mining
News

Powder Technology, 384, 36–50. https://doi.org/10.1016/j.powtec.2021.02.003 ... terms of bubble size and foam stability across different pHs and dosages, ...

Dec 18, 2025 View →
Fundamentals of Field Crop Breeding Springer 2022 | PDF | Plant ...
News

The PHS in wheat is characterised by premature germination of kernels in ... https://doi.org/10.1016/j.cj.2021.02.003. Liao S, Qin X, Luo L et al (2019) ...

Dec 18, 2025 View →
Surgry Update 2021 MAMC | PDF | Science & Mathematics
News

10.1016/j.eururo.2017.11.001. Epub 2017 Nov 22. PMID: 29174580. 6. Nicolau C ... 2021.02.003. • El Boghdady M, Ewalds-Kvist BM. Laparoscopic Surgery ...

Dec 18, 2025 View →
New Tool Helps Providers Navigate Adalimumab Biosimilars ...
News

J Pharm Sci. 2021;110(4):1572-1582. doi:10.1016/j.xphs.2021.02.003. 2. Giavatto C, Mourani J, Fitzpatrick C, Hardin B, et al. Biosimilar ...

Mar 14, 2024 View →
New Advances in the Bioprocess Pipeline | Technology Networks
News

doi: 10.1016/j.ddtec.2021.02.003 2. D'Amico CI, Robbins G, Po I, et ... xphs.2023.01.012 4. Lambiase G, Klottrup-Rees K, Lovelady C, et ...

Sep 25, 2023 View →